This content is from: Premium These Biopharma Funds Made a Comeback Last Year While some funds posted huge losses in 2022, several others managed to turn sharp losses into profitability. By Stephen Taub January 19, 2023
This content is from: Premium Glenview Posts Mixed Results in 2022 One of the firm’s main funds made money, while the other lost less than half what the S&P 500 did. By Stephen Taub January 09, 2023
This content is from: Premium JW Asset Management Has a Sobering Year The firm’s big bet on cannabis paid off big in 2020 — but 2022 is a different story. By Stephen Taub December 19, 2022
This content is from: Premium RA Capital’s SPAC Merger Bet The biopharma specialist could be signaling renewed confidence in the overall VC market. By Stephen Taub November 28, 2022
This content is from: Premium Light Street’s 2022 Keeps Getting Worse The Tiger Grandcub is among several Tiger Management descendants that are poised to post their worst results ever. By Stephen Taub December 12, 2022
This content is from: Premium Druckenmiller Expands His Stock Portfolio The legendary macro trader’s Duquesne Family Office made several new buys and slashed several key positions in the third quarter. By Stephen Taub November 17, 2022
